Showing 4461-4470 of 10240 results for "".
- Late-Breaking Data: Skyrizi Achieves Superior Rates of Complete Skin Clearance for Psoriasis Compared to Secukinumab at 52 Weekshttps://practicaldermatology.com/news/late-breaking-data-show-skyrizi-achieves-superior-rates-of-complete-skin-clearance-for-psoriasis-compared-to-secukinumab-at-52-weeks/2460423/New late-breaking Phase 3b head-to-head data show superior rates of skin clearance for AbbVie's risankizumab-rzaa (Skyrizi) compared to secukinumab (Cosentyx) at week 52. Sixty-six percent of psoriasis patients receiving Skyrizi achieved completely clear skin—100 percent clearance in th
- Dermavant Completes Enrollment for Long-Term Safety Study of Tapinarof in Adult Psoriasishttps://practicaldermatology.com/news/dermavant-completes-enrollment-for-long-term-safety-study-of-tapinarof-in-adult-psoriasis/2460416/Patient enrollment in Dermavant’s long-term safety study of tapinarof is now complete, the company says. Tapinarof is a potential first-in-class, once-daily topical therapeutic aryl hydrocarbon receptor modulating agent (TAMA) being investigated for use in adult patients diagnosed with plaq
- SciBase Receives FDA Approval for Nevisense 3.0https://practicaldermatology.com/news/scibase-receives-fda-approval-for-nevisense-30/2460388/The FDA has approved SciBase AB's Nevisense 3.0, the third generation of their Nevisense system for early melanoma detection. Nevisense, an AI-based point-of-care system for the non-invasive evaluation of irregular moles remains the only FDA approved system available for melanoma detection in
- Positive Top-Line Results Seen for Otezla in Mild-To-Moderate Plaque Psoriasishttps://practicaldermatology.com/news/positive-top-line-results-seen-for-otezla-in-mild-to-moderate-plaque-psoriasis/2460382/Amgen’s Otezla produces significant improvements in measures of mild-to-moderate psoriasis, compared with placebo, according to a top-line results from the ADVANCE trial. ADVANCE is a Phase 3, multicenter, randomized, placebo-controlled, double-blind study to assess the efficacy o
- Suneva to Distribute Sinclair Pharma's Silhouette Instalift Sutureshttps://practicaldermatology.com/news/suneva-to-distribute-sinclair-pharmas-silhouette-instalift-sutures/2460372/Suneva Medical, Inc. is the exclusive North American distributor for Sinclair Pharma's Silhouette Instalift sutures "We are excited to welcome Silhouette Instalift to our already broad regenerative aesthetics portfolio,"
- Bimini Health Tech’s Dermapose Access Office-Based Fat Harvesting System Scores FDA 510(k) clearancehttps://practicaldermatology.com/news/bimini-health-techs-dermapose-access-office-based-fat-harvesting-system-scores-fda-510k-clearance/2460368/Bimini Health Tech’s received US Food and Drug Administration (FDA) 510(k) clearance for its Dermapose Access, a novel fat harvesting system. Designed for office use, the launch of the Dermapose Access sy
- AAD Survey: Most Americans Know Sun Protection Is Important, Still Don't Protect Themselveshttps://practicaldermatology.com/news/aad-survey-most-americans-know-sun-protection-is-important-but-still-dont-protect-themselves-1/2460367/Fully 76 percent of Americans agree that sun protection is an important healthy habit, yet only 41 percent report regularly protecting themselves outdoors — increasing their risk for skin cancer, according to a new survey from the American Academy of Dermatology. What’s more
- MD Survey: Telehealth Booming, Prescribing Habits Changing During Pandemichttps://practicaldermatology.com/news/md-survey-telehealth-booming-prescribing-habits-changing-during-pandemic/2460360/More than four-fifths of physicians saw fewer patients in late March, averaging 40 patients per week vs. 103 per week prior to March 2020, according to a new survey of 500 U.S physicians by AbelsonTaylor, a health and wellness marketing agency. What’s more, three-quarters of physi
- Label Expansion: Amgen's Otezla Adds Scalp Datahttps://practicaldermatology.com/news/label-expansion-amgens-otezla-adds-scalp-data/2460359/With FDA approval of a supplemental New Drug Application (sNDA), the label for Amgen's Otezla will now be updated to include scalp psoriasis data from the Phase 3 STYLE trial. The label expansion makes Otezla the only oral treatment option to have data specific to moderate
- Can JAK Inhibition Put the Brakes on COVID-19-Associated Cytokine Storm? Incyte Hopes Sohttps://practicaldermatology.com/news/can-jak-inhibition-put-the-brakes-on-covid-19-associated-cytokine-storm-incyte-hopes-so/2460355/Incyte’s JAK inhibitor may play a role in stopping COVID-19-associated cytokine storms. Incyte is starting RUXCOVID, a global, randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating the efficacy and safety of ruxolit